EuroBiotech: More Articles of Note

newspapers
(Pixabay)

> NEC and Vaximm teamed up to develop personalized cancer vaccines. The project will make use of NEC’s artificial intelligence technology. Statement

> Leo Pharma exercised its option on compounds identified by HitGen. The decision marks a milestone in the relationship between the companies that began in 2015. Release

> Compugen posted initial phase 1 data on its anti-PVRIG antibody. The trial detected early signs of efficacy in microsatellite stable colorectal cancer. Statement
 
> Lytix Biopharma formed a clinical collaboration with Iovance Biotherapeutics. The companies will test Lytix’s oncolytic peptide in combination with Iovance’s T-cell therapy. Release

Webinar

How ICON, Lotus, and Bioforum are Improving Study Efficiency with a Modern EDC

CROs are often at the forefront of adopting new technologies to make clinical trials more efficient. Hear how ICON, Lotus Clinical Research, and Bioforum are speeding database builds and automating reporting tasks for data management.

> Poxel said FDA feedback supports its plan to use the 505(b)(2) pathway to file for approval in nonalcoholic steatohepatitis. The French biotech plans to rely on Actos data in its filing. Statement

> Lunac Therapeutics spun out of the University of Leeds with £2.7 million ($3.5 million) in series A funding. The first close of the round will support work on anticoagulants. Release 

Suggested Articles

NASH leaders weigh in on the need for a drug for the disease and the challenges in getting it to patients.

The $210 million fund began life by leading a $17 million series A round in Quellis Biosciences.

The nine-story building will house Amgen’s Bay Area employees when it opens early in 2022.